With this collaboration, Respiree’s patient monitoring solution will be made available for healthcare professionals in APAC through a pilot program using Roche’s blood glucose monitoring system. The goal is to simplify clinical workflows and augment diagnostic and monitoring capabilities, leading to improved patient outcomes.
Respiree announced today that it has incorporated in the US and will be incubating within Johnson & Johnson Innovation – JLABS @ South San Francisco from February 12, 2024. By expanding footprint within the US, Respiree aims to deepen its relationships and networks within the pharma and life science sector. Respiree was formerly a company at JLABS in Singapore.
It is part of the hospital’s smart remote health monitoring system project with A*STAR spinoff Respiree.
Changi General Hospital developing AI algorithms to predict patient deterioration Read More
